Calithera Biosciences Inc (CALA) Research Coverage Started at William Blair
Investment analysts at William Blair started coverage on shares of Calithera Biosciences Inc (NASDAQ:CALA) in a report issued on Thursday, MarketBeat.com reports. The brokerage set an “outperform” rating on the biotechnology company’s stock.
CALA has been the topic of several other reports. Zacks Investment Research upgraded shares of Calithera Biosciences from a “hold” rating to a “strong-buy” rating and set a $21.00 target price on the stock in a report on Tuesday, July 11th. BidaskClub downgraded shares of Calithera Biosciences from a “sell” rating to a “strong sell” rating in a report on Saturday, August 12th. Finally, HC Wainwright restated a “buy” rating and set a $19.00 target price (up from $14.00) on shares of Calithera Biosciences in a report on Monday, June 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $15.50.
Shares of Calithera Biosciences (NASDAQ:CALA) traded up 1.26% on Thursday, reaching $16.05. 368,725 shares of the company were exchanged. The stock has a 50 day moving average price of $15.62 and a 200-day moving average price of $14.33. Calithera Biosciences has a 12 month low of $2.20 and a 12 month high of $20.05. The stock’s market capitalization is $569.39 million.
Calithera Biosciences (NASDAQ:CALA) last announced its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.14. The firm had revenue of $7.26 million for the quarter, compared to the consensus estimate of $4.80 million. Calithera Biosciences had a negative net margin of 71.59% and a negative return on equity of 12.70%. On average, equities analysts expect that Calithera Biosciences will post ($0.83) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/05/calithera-biosciences-inc-cala-research-coverage-started-at-william-blair.html.
In other news, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of Calithera Biosciences stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $15.64, for a total value of $9,008,640.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Keith Orford sold 2,120 shares of Calithera Biosciences stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $18.31, for a total transaction of $38,817.20. The disclosure for this sale can be found here. 16.30% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of CALA. Raymond James Financial Services Advisors Inc. acquired a new stake in shares of Calithera Biosciences in the first quarter valued at approximately $117,000. Legal & General Group Plc acquired a new stake in shares of Calithera Biosciences in the second quarter valued at approximately $120,000. Nationwide Fund Advisors acquired a new stake in shares of Calithera Biosciences in the first quarter valued at approximately $131,000. KCG Holdings Inc. acquired a new stake in shares of Calithera Biosciences in the first quarter valued at approximately $144,000. Finally, Paloma Partners Management Co acquired a new stake in shares of Calithera Biosciences in the first quarter valued at approximately $160,000. Institutional investors own 71.88% of the company’s stock.
About Calithera Biosciences
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Ratings for Calithera Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.